Sensulin
2 known investors
Sensulin is a preclinical biopharmaceutical company developing glucose-responsive insulin therapies for type 1 and type 2 diabetes that aim to reduce hypoglycemia risk and daily injection requirements. The company's technology targets long-term complications of diabetes while potentially eliminating the need for separate basal and mealtime insulin dosing.
Founders & leadership
DB
Dan BradburyinπExecutive Chairman and Co-FounderDan Bradbury is Executive Chairman and Co-Founder of Sensulin, a preclinical biopharmaceutical company developing glucose-responsive insulin therapies for diabetes. He has over 40 years of experience in life sciences executive roles focused on business strategy and bringing novel medicines to market.
MM
Board
Investors Β· 2
Competitors Β· 3
by search overlapBiPar Sciences6 shared keywordsBiopharmaceutical developer of tumor-selective PARP inhibitor cancer therapies, acquired by Sanofi-aventis in 2009.
Diabetes5 shared keywordsA nonprofit organization that provides educational resources and information about prediabetes, including prevention strategies and lifestyle management for Americans at risk of developing type 2 diabetes.
Medscape4 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
Companies competing with Sensulin for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding Β· 1 SBIR/STTR award
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase ISTTR | 2014 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Sensulin do?
- Sensulin is a preclinical biopharmaceutical company developing glucose-responsive insulin therapies for type 1 and type 2 diabetes that aim to reduce hypoglycemia risk and daily injection requirements. The company's technology targets long-term complications of diabetes while potentially eliminating the need for separate basal and mealtime insulin dosing.
- Who founded Sensulin?
- Sensulin was founded by Dan Bradbury.
- Who are Sensulin's investors?
- Sensulin's investors include BioBrit, Cortado Ventures.